What is the impact of the 2017 cochrane systematic review and meta-analysis that evaluated the use of PCSK9 inhibitors for lowering cardiovascular disease and mortality?

被引:6
作者
Jalloh, Mohamed A. [1 ]
Ip, Eric J. [1 ]
Doroudgar, Shadi [1 ]
机构
[1] Touro Univ Calif, Coll Pharm, Clin Sci, Vallejo, CA 94592 USA
关键词
PCSK9; inhibitors; systematic review; meta-analysis; cardiovascular disease and mortality; CHOLESTEROL; EFFICACY; THERAPY; TRIALS; SAFETY; LDL;
D O I
10.1080/14656566.2018.1464558
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: In 2017, Schmidt et al. conducted a Cochrane systematic review and meta-analysis to evaluate the effect of using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce low-density-lipoprotein- cholesterol (LDL-C) and cardiovascular disease (CVD). The Cochrane review was a systematic review and meta-analysis of 20 randomized, double-blinded trials that compared the use of PCSK9 inhibitors with statins/ezetimibe, ezetimibe, or placebo for a treatment duration of at least 24weeks. The use of PCSK9 inhibitors lowered the risk for CVD (OR 0.86 (0.80 to 0.92)) but not mortality (OR 1.02 (0.91 to 1.14)) when compared to placebo.Areas covered: The following article evaluates the recently published Cochrane review and clarifies the efficacy of PCSK9 inhibitors for improving cardiovascular morbidity and mortality.Expert opinion: The Cochrane review discussed suggests that PCSK9 inhibitors are effective in lowering LDL-C and the risk of CVD but not the risk of mortality. The higher price of PCSK9 inhibitors is a further deterrent for using them as a substitute for statins - cholesterol lowering medications with history showing they lower mortality. Statins should remain the gold-standard cholesterol-lowering drug class until PCSK9 inhibitors become more affordable and demonstrate consistent efficacy for reducing CVD and mortality.
引用
收藏
页码:739 / 741
页数:3
相关论文
共 50 条
[41]   Effects of PCSK9 inhibitors on coronary microcirculation, inflammation and cardiac function in patients with CHD after PCI: a protocol for systematic review and meta-analysis [J].
Ye, Xuejiao ;
Wang, Shihan ;
Liu, Xiao'an ;
Wu, Qian ;
Lv, Yanfei ;
Lv, Qianyu ;
Li, Junjia ;
Li, Lanlan ;
Yang, Yingtian .
BMJ OPEN, 2023, 13 (09)
[42]   Psychological Interventions for Coronary Heart Disease: Cochrane Systematic Review and Meta-analysis [J].
Whalley, Ben ;
Thompson, David R. ;
Taylor, Rod S. .
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2014, 21 (01) :109-121
[43]   The Association Between PCSK9 Inhibitor Use and Sepsis: A Systematic Review and Meta-Analysis of 20 Double-Blind, Randomized, Placebo-Controlled Trials [J].
Zhou, Zhen ;
Zhang, Wei ;
Burgner, David ;
Tonkin, Andrew ;
Zhu, Chao ;
Sun, Chenyu ;
Magnussen, Costan G. ;
Ernst, Michael E. ;
Breslin, Monique ;
Nicholls, Stephen J. ;
Nelson, Mark R. .
AMERICAN JOURNAL OF MEDICINE, 2023, 136 (06) :558-567.e20
[44]   In-hospital initiation of a PCSK9 inhibitor in patients with acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials [J].
Shi, Wenhai ;
Xu, Yong ;
Zhou, Lin ;
Wang, Wuwan ;
Huang, Wei ;
Zhou, Bo .
MEDICINE, 2024, 103 (10) :E37416
[45]   The effect of folic acid in patients with cardiovascular disease A systematic review and meta-analysis [J].
Wang, Yuan ;
Jin, Yang ;
Wang, Yao ;
Li, Li ;
Liao, Yanhong ;
Zhang, Yun ;
Yu, Dan .
MEDICINE, 2019, 98 (37)
[46]   Impact of gout on cardiovascular disease mortality: a meta-analysis [J].
Yuan, Jielin ;
Xie, Zhitao ;
Pan, Bo ;
Zhang, Jingchang .
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (SUPPL 3) :329-337
[47]   Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials [J].
Yang, Na ;
He, Li-Yun ;
Liu, Peng ;
Li, Zi-Yi ;
Yang, Yu-Cheng ;
Ping, Fan ;
Xu, Ling-Ling ;
Li, Wei ;
Zhang, Hua-Bing ;
Li, Yu-Xiu .
WORLD JOURNAL OF DIABETES, 2024, 15 (05)
[48]   Impact of PCSK9 mutations on incidences of hypercholesterolemia: A meta-analysis to infer correlation [J].
Singhal, Monisha ;
Agrawal, Raadhika ;
Gupta, Nidhi .
META GENE, 2022, 31
[49]   Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis [J].
Ghasempour, Ghasem ;
Zamani-Garmsiri, Fahimeh ;
Shaikhnia, Farhad ;
Soleimani, Ali Akbar ;
Fard, Syed Reza Hosseini ;
Leila, Janani ;
Teimuri, Shohreh ;
Parvaz, Najmeh ;
Mohammadi, Payam ;
Najafi, Mohammad .
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (02) :223-241
[50]   Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies [J].
Xiao, Yunjun ;
Peng, Chaoqiong ;
Huang, Wei ;
Zhang, Jinzhou ;
Gao, Yang ;
Kim, Jean H. ;
Yeoh, Eng-kiong ;
Su, Xuefen .
CIRCULATION JOURNAL, 2017, 81 (08) :1150-1157